Concourse Financial Group Securities, Inc. V Tv Therapeutics Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.52 Billion
  • Q1 2024

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 30, 2023
BUY
$0.42 - $0.75 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$0.42 - $0.75 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$0.72 - $0.95 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$0.72 - $1.01 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.66 - $1.02 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$0.65 - $1.37 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.39 - $0.84 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$0.51 - $1.0 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$0.95 - $1.69 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$1.53 - $2.22 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$2.27 - $3.44 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$1.97 - $2.89 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$1.49 - $3.1 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$1.7 - $2.98 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$1.74 - $3.19 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020
BUY
$1.63 - $3.75 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020
BUY
$1.37 - $1.97 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019
BUY
$1.26 - $1.77 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019
BUY
$1.29 - $1.83 $0 - $0
0 New
0 $0
Q1 2019

May 15, 2019
BUY
$1.67 - $3.12 $0 - $0
0 New
0 $0
Q4 2018

Feb 14, 2019
BUY
$0.78 - $3.74 $0 - $0
0 New
0 $0
Q3 2018

Nov 13, 2018
BUY
$0.7 - $1.58 $0 - $0
0 New
0 $0

Others Institutions Holding VTVT

# of Institutions
1
Shares Held
243K
Call Options Held
0
Put Options Held
0
View Full List

About vTv Therapeutics Inc.

VTVT Quotes by TradingView
  • Ticker VTVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,483,600
  • Market Cap $1.43B
  • Description
  • vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...
More about VTVT
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email